{"protocolSection": {"identificationModule": {"nctId": "NCT00993187", "orgStudyIdInfo": {"id": "0431A-202"}, "secondaryIdInfos": [{"id": "2009_672", "type": "OTHER", "domain": "Merck Registration Number"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)", "officialTitle": "A Multicenter, Randomized, Double Blind Study to Compare the Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (Janumet\u00ae) Compared to Glimepiride in Patients With Type 2 Diabetes Mellitus"}, "statusModule": {"statusVerifiedDate": "2018-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-05-04", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2013-10-29", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-10-29", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-10-09", "studyFirstSubmitQcDate": "2009-10-09", "studyFirstPostDateStruct": {"date": "2009-10-12", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2014-09-08", "resultsFirstSubmitQcDate": "2014-09-08", "resultsFirstPostDateStruct": {"date": "2014-09-15", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2018-07-24", "lastUpdatePostDateStruct": {"date": "2018-08-22", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study will assess the effect of sitagliptin/metformin FDC 50/1000 mg (Janumet\u00ae), MK-0431A) compared with the effect of glimepiride on hemoglobin A1c (HbA1c). The primary hypothesis is that after 30 weeks, sitagliptin/metformin FDC 50/1000 mg provides superior reduction in HbA1c (mean change from baseline) compared to glimepiride."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 292, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Sitagliptin/Metformin FDC", "type": "EXPERIMENTAL", "description": "Participants in the Sitagliptin/Metformin Fixed- Dose Combination (Sita/Met FDC) group received tablets of Sita/Met FDC and placebo tablets matching glimepiride for 30 weeks. The dose for Sita/Met FDC was 50/500 mg twice daily (b.i.d.) starting Day 1 and increased to 50/1000 mg b.i.d. over a period of 4 weeks.", "interventionNames": ["Drug: Sitagliptin/Metformin FDC", "Drug: Matching placebo to glimepiride"]}, {"label": "Glimepiride", "type": "ACTIVE_COMPARATOR", "description": "Participants in the Glimepiride group received 2 placebo tablets matching Sita/Met FDC and glimepiride tablets (1 mg or 2 mg) for 30 weeks. The dose for glimepiride was 1 mg once daily (q.d.) starting Day 1 and up-titrated as considered appropriate by the investigator based upon the results of participant's self-monitored blood glucose levels but not to exceed 6 mg/day.", "interventionNames": ["Drug: Comparator: Glimepiride", "Drug: Matching placebo to Sitagliptin/Metformin FDC"]}], "interventions": [{"type": "DRUG", "name": "Sitagliptin/Metformin FDC", "description": "Sitagliptin phosphate plus metformin hydrochloride combination tablet (MK-0431A) orally up to 50/1000 mg BID for 30 weeks", "armGroupLabels": ["Sitagliptin/Metformin FDC"], "otherNames": ["Janumet\u00ae"]}, {"type": "DRUG", "name": "Comparator: Glimepiride", "description": "Glimepiride tablet orally up to 6 mg daily for 30 Weeks", "armGroupLabels": ["Glimepiride"], "otherNames": ["Amaryl\u00ae"]}, {"type": "DRUG", "name": "Matching placebo to Sitagliptin/Metformin FDC", "description": "Matching placebo to Sitagliptin/Metformin FDC 50/1000 mg orally BID for 30 weeks", "armGroupLabels": ["Glimepiride"]}, {"type": "DRUG", "name": "Matching placebo to glimepiride", "description": "Matching placebo to glimepiride tablet orally daily for 30 weeks", "armGroupLabels": ["Sitagliptin/Metformin FDC"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Hemoglobin A1C (HbA1C) at Week 30", "description": "HbA1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%). Change in A1C following 30 weeks of therapy (i.e., A1C at Week 30 minus A1C at baseline).", "timeFrame": "Baseline and Week 30"}, {"measure": "Number of Participants Who Experienced at Least One Adverse Event (AE)", "description": "An adverse event (AE) is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product.", "timeFrame": "Up to 32 weeks"}, {"measure": "Number of Participants Who Discontinued Study Drug Due to an Adverse Event", "description": "An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product.", "timeFrame": "Up to 30 weeks"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 30", "description": "Blood glucose was measured on a fasting basis (collected after an 8- to 10-hour fast). FPG is expressed as mg/dL. Blood was drawn at predose on Day 1 and after 30 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 30 minus FPG at baseline).", "timeFrame": "Baseline and Week 30"}, {"measure": "Percentage of Participants With One or More Episodes of Hypoglycemia", "description": "Symptomatic episodes assessed as likely to be due to hypoglycemia were reported by investigators as adverse experiences of hypoglycemia. Adverse experiences of hypoglycemia were based on all reports of hypoglycemia; a concurrent glucose measurement was not required.", "timeFrame": "Up to Week 30"}, {"measure": "Change From Baseline in Body Weight at Week 30", "description": "Change in body weight following 30 weeks of therapy (i.e., body weight at Week 30 minus body weight at baseline)", "timeFrame": "Baseline and Week 30"}, {"measure": "Percentage of Participants With HbA1C < 7.0% at Week 30", "description": "HbA1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%).", "timeFrame": "Week 30"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Has type 2 diabetes mellitus\n* Is currently not on an anti-hypoglycemic agent (AHA) (off for at least 12 weeks) and has a Visit 1/Screening Visit HbA1c greater than or equal to 7.0% and less than or equal to 9.5%; or is currently on AHA monotherapy or low-dose oral combination therapy (i.e., less than or equal to 50% maximum labeled dose of each agent) and has a Visit 1/Screening Visit HbA1c greater than or equal to 6.5% and less than or equal to 9.0%\n\nExclusion Criteria:\n\n* Has a history of type 1 diabetes mellitus or a history of ketoacidosis\n* Has been on any investigational or approved glucagon-like peptide-1 (GLP-1) analogue (such as exenatide, liraglutide, etc.), any investigational or approved dipeptidyl peptidase IV (DPP-4) inhibitor (such as sitagliptin, vildagliptin, alogliptin, etc.) or a peroxisome proliferator-activated receptor (PPAR) gamma agonist agent (such as rosiglitazone, pioglitazone, etc.) within 12 weeks of Visit 1\n* Required insulin within the prior 12 weeks\n* Has a hypersensitivity or contraindication to any sulfonylurea medication (such as glimepiride, glipizide, etc.), DPP-4 inhibitor (such as sitagliptin, vildagliptin, alogliptin, etc.), or biguanide medication (such as metformin, etc.)\n* Has inadequately controlled hypertension\n* Has cirrhosis or active liver disease\n* Has severe cardiac conditions\n* Is obese\n* Has human immunodeficiency virus (HIV)", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "27229178", "type": "RESULT", "citation": "Kim SS, Kim IJ, Lee KJ, Park JH, Kim YI, Lee YS, Chung SC, Lee SJ. Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study. J Diabetes. 2017 Apr;9(4):412-422. doi: 10.1111/1753-0407.12432. Epub 2016 Aug 8."}], "availIpds": [{"type": "CSR Synopsis", "url": "http://www.merck.com/clinical-trials/study.html?id=0431A-202&kw=NCT00993187&tab=access"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf", "url": "http://engagezone.msd.com/ds_documentation.php"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Sitagliptin/Metformin", "description": "Participants in the Sitagliptin/Metformin Fixed- Dose Combination (Sita/Met FDC) group received tablets of Sita/Met FDC and placebo tablets matching glimepiride for 30 weeks. The dose for Sita/Met FDC was 50/500 mg twice daily (b.i.d.) starting Day 1 and increased to 50/1000 mg b.i.d. over a period of 4 weeks."}, {"id": "FG001", "title": "Glimepiride", "description": "Participants in the Glimepiride group received 2 placebo tablets matching Sita/Met FDC and glimepiride tablets (1 mg or 2 mg) for 30 weeks. The dose for glimepiride was 1 mg once daily (q.d.) starting Day 1 and up-titrated as considered appropriate by the investigator based upon the results of participant's self-monitored blood glucose levels but not to exceed 6 mg/day."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "147"}, {"groupId": "FG001", "numSubjects": "145"}]}, {"type": "Received at Least 1 Dose of Study Drug", "achievements": [{"groupId": "FG000", "numSubjects": "146"}, {"groupId": "FG001", "numSubjects": "144"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "121"}, {"groupId": "FG001", "numSubjects": "108"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "26"}, {"groupId": "FG001", "numSubjects": "37"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Sitagliptin/Metformin", "description": "Participants in the Sitagliptin/Metformin Fixed- Dose Combination (Sita/Met FDC) group received tablets of Sita/Met FDC and placebo tablets matching glimepiride for 30 weeks. The dose for Sita/Met FDC was 50/500 mg twice daily (b.i.d.) starting Day 1 and increased to 50/1000 mg b.i.d. over a period of 4 weeks."}, {"id": "BG001", "title": "Glimepiride", "description": "Participants in the Glimepiride group received 2 placebo tablets matching Sita/Met FDC and glimepiride tablets (1 mg or 2 mg) for 30 weeks. The dose for glimepiride was 1 mg once daily (q.d.) starting Day 1 and up-titrated as considered appropriate by the investigator based upon the results of participant's self-monitored blood glucose levels but not to exceed 6 mg/day."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "147"}, {"groupId": "BG001", "value": "145"}, {"groupId": "BG002", "value": "292"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "54.8", "spread": "8.5"}, {"groupId": "BG001", "value": "53.1", "spread": "9.2"}, {"groupId": "BG002", "value": "53.9", "spread": "8.9"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "66"}, {"groupId": "BG001", "value": "61"}, {"groupId": "BG002", "value": "127"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "81"}, {"groupId": "BG001", "value": "84"}, {"groupId": "BG002", "value": "165"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Hemoglobin A1C (HbA1C) at Week 30", "description": "HbA1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%). Change in A1C following 30 weeks of therapy (i.e., A1C at Week 30 minus A1C at baseline).", "populationDescription": "Full-Analysis-Set (FAS) Population included all randomized participants who had a baseline measurement, consumed at least one dose of study medication, and had at least one post-randomization measurement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent of total hemoglobin", "timeFrame": "Baseline and Week 30", "groups": [{"id": "OG000", "title": "Sitagliptin/Metformin", "description": "Participants in the Sitagliptin/Metformin Fixed- Dose Combination (Sita/Met FDC) group received tablets of Sita/Met FDC and placebo tablets matching glimepiride for 30 weeks. The dose for Sita/Met FDC was 50/500 mg twice daily (b.i.d.) starting Day 1 and increased to 50/1000 mg b.i.d. over a period of 4 weeks."}, {"id": "OG001", "title": "Glimepiride", "description": "Participants in the Glimepiride group received 2 placebo tablets matching Sita/Met FDC and glimepiride tablets (1 mg or 2 mg) for 30 weeks. The dose for glimepiride was 1 mg once daily (q.d.) starting Day 1 and up-titrated as considered appropriate by the investigator based upon the results of participant's self-monitored blood glucose levels but not to exceed 6 mg/day."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "138"}, {"groupId": "OG001", "value": "137"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.5", "lowerLimit": "-1.6", "upperLimit": "-1.4"}, {"groupId": "OG001", "value": "-0.7", "lowerLimit": "-0.8", "upperLimit": "-0.6"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Difference in Least Squares Mean", "paramValue": "-0.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.0", "ciUpperLimit": "-0.6"}]}, {"type": "PRIMARY", "title": "Number of Participants Who Experienced at Least One Adverse Event (AE)", "description": "An adverse event (AE) is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product.", "populationDescription": "The All Patients as Treated (APaT) Population includes all randomized participants who received at least 1 dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Up to 32 weeks", "groups": [{"id": "OG000", "title": "Sitagliptin/Metformin", "description": "Participants in the Sitagliptin/Metformin Fixed- Dose Combination (Sita/Met FDC) group received tablets of Sita/Met FDC and placebo tablets matching glimepiride for 30 weeks. The dose for Sita/Met FDC was 50/500 mg twice daily (b.i.d.) starting Day 1 and increased to 50/1000 mg b.i.d. over a period of 4 weeks."}, {"id": "OG001", "title": "Glimepiride", "description": "Participants in the Glimepiride group received 2 placebo tablets matching Sita/Met FDC and glimepiride tablets (1 mg or 2 mg) for 30 weeks. The dose for glimepiride was 1 mg once daily (q.d.) starting Day 1 and up-titrated as considered appropriate by the investigator based upon the results of participant's self-monitored blood glucose levels but not to exceed 6 mg/day."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "146"}, {"groupId": "OG001", "value": "144"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "88"}, {"groupId": "OG001", "value": "101"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants Who Discontinued Study Drug Due to an Adverse Event", "description": "An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product.", "populationDescription": "The APaT Population includes all randomized participants who received at least 1 dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Up to 30 weeks", "groups": [{"id": "OG000", "title": "Sitagliptin/Metformin", "description": "Participants in the Sitagliptin/Metformin Fixed- Dose Combination (Sita/Met FDC) group received tablets of Sita/Met FDC and placebo tablets matching glimepiride for 30 weeks. The dose for Sita/Met FDC was 50/500 mg twice daily (b.i.d.) starting Day 1 and increased to 50/1000 mg b.i.d. over a period of 4 weeks."}, {"id": "OG001", "title": "Glimepiride", "description": "Participants in the Glimepiride group received 2 placebo tablets matching Sita/Met FDC and glimepiride tablets (1 mg or 2 mg) for 30 weeks. The dose for glimepiride was 1 mg once daily (q.d.) starting Day 1 and up-titrated as considered appropriate by the investigator based upon the results of participant's self-monitored blood glucose levels but not to exceed 6 mg/day."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "146"}, {"groupId": "OG001", "value": "144"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "8"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 30", "description": "Blood glucose was measured on a fasting basis (collected after an 8- to 10-hour fast). FPG is expressed as mg/dL. Blood was drawn at predose on Day 1 and after 30 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 30 minus FPG at baseline).", "populationDescription": "The FAS Population included all randomized participants who had a baseline measurement, consumed at least one dose of study medication, and had at least one post-randomization measurement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 30", "groups": [{"id": "OG000", "title": "Sitagliptin/Metformin", "description": "Participants in the Sitagliptin/Metformin Fixed- Dose Combination (Sita/Met FDC) group received tablets of Sita/Met FDC and placebo tablets matching glimepiride for 30 weeks. The dose for Sita/Met FDC was 50/500 mg twice daily (b.i.d.) starting Day 1 and increased to 50/1000 mg b.i.d. over a period of 4 weeks."}, {"id": "OG001", "title": "Glimepiride", "description": "Participants in the Glimepiride group received 2 placebo tablets matching Sita/Met FDC and glimepiride tablets (1 mg or 2 mg) for 30 weeks. The dose for glimepiride was 1 mg once daily (q.d.) starting Day 1 and up-titrated as considered appropriate by the investigator based upon the results of participant's self-monitored blood glucose levels but not to exceed 6 mg/day."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "138"}, {"groupId": "OG001", "value": "137"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-47.0", "lowerLimit": "-51.7", "upperLimit": "-42.3"}, {"groupId": "OG001", "value": "-23.5", "lowerLimit": "-28.2", "upperLimit": "-18.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Difference in Least Squares Mean", "paramValue": "-23.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-30.0", "ciUpperLimit": "-16.9"}]}, {"type": "SECONDARY", "title": "Percentage of Participants With One or More Episodes of Hypoglycemia", "description": "Symptomatic episodes assessed as likely to be due to hypoglycemia were reported by investigators as adverse experiences of hypoglycemia. Adverse experiences of hypoglycemia were based on all reports of hypoglycemia; a concurrent glucose measurement was not required.", "populationDescription": "The APaT Population includes all randomized participants who received at least 1 dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Up to Week 30", "groups": [{"id": "OG000", "title": "Sitagliptin/Metformin", "description": "Participants in the Sitagliptin/Metformin Fixed- Dose Combination (Sita/Met FDC) group received tablets of Sita/Met FDC and placebo tablets matching glimepiride for 30 weeks. The dose for Sita/Met FDC was 50/500 mg twice daily (b.i.d.) starting Day 1 and increased to 50/1000 mg b.i.d. over a period of 4 weeks."}, {"id": "OG001", "title": "Glimepiride", "description": "Participants in the Glimepiride group received 2 placebo tablets matching Sita/Met FDC and glimepiride tablets (1 mg or 2 mg) for 30 weeks. The dose for glimepiride was 1 mg once daily (q.d.) starting Day 1 and up-titrated as considered appropriate by the investigator based upon the results of participant's self-monitored blood glucose levels but not to exceed 6 mg/day."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "146"}, {"groupId": "OG001", "value": "144"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.5"}, {"groupId": "OG001", "value": "20.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Difference in percent", "paramValue": "-14.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-23.0", "ciUpperLimit": "-7.0"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Body Weight at Week 30", "description": "Change in body weight following 30 weeks of therapy (i.e., body weight at Week 30 minus body weight at baseline)", "populationDescription": "The APaT Population includes all randomized participants who received at least 1 dose of study medication.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "kg", "timeFrame": "Baseline and Week 30", "groups": [{"id": "OG000", "title": "Sitagliptin/Metformin", "description": "Participants in the Sitagliptin/Metformin Fixed- Dose Combination (Sita/Met FDC) group received tablets of Sita/Met FDC and placebo tablets matching glimepiride for 30 weeks. The dose for Sita/Met FDC was 50/500 mg twice daily (b.i.d.) starting Day 1 and increased to 50/1000 mg b.i.d. over a period of 4 weeks."}, {"id": "OG001", "title": "Glimepiride", "description": "Participants in the Glimepiride group received 2 placebo tablets matching Sita/Met FDC and glimepiride tablets (1 mg or 2 mg) for 30 weeks. The dose for glimepiride was 1 mg once daily (q.d.) starting Day 1 and up-titrated as considered appropriate by the investigator based upon the results of participant's self-monitored blood glucose levels but not to exceed 6 mg/day."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "146"}, {"groupId": "OG001", "value": "144"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.83", "spread": "1.8", "lowerLimit": "-1.16", "upperLimit": "-0.49"}, {"groupId": "OG001", "value": "0.90", "spread": "2.4", "lowerLimit": "0.56", "upperLimit": "1.23"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Difference in Least Squares Mean", "paramValue": "-1.72", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.20", "ciUpperLimit": "-1.25"}]}, {"type": "SECONDARY", "title": "Percentage of Participants With HbA1C < 7.0% at Week 30", "description": "HbA1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%).", "populationDescription": "The FAS Population included all randomized participants who had a baseline measurement, consumed at least one dose of study medication, and had at least one post-randomization measurement.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Week 30", "groups": [{"id": "OG000", "title": "Sitagliptin/Metformin", "description": "Participants in the Sitagliptin/Metformin Fixed- Dose Combination (Sita/Met FDC) group received tablets of Sita/Met FDC and placebo tablets matching glimepiride for 30 weeks. The dose for Sita/Met FDC was 50/500 mg twice daily (b.i.d.) starting Day 1 and increased to 50/1000 mg b.i.d. over a period of 4 weeks."}, {"id": "OG001", "title": "Glimepiride", "description": "Participants in the Glimepiride group received 2 placebo tablets matching Sita/Met FDC and glimepiride tablets (1 mg or 2 mg) for 30 weeks. The dose for glimepiride was 1 mg once daily (q.d.) starting Day 1 and up-titrated as considered appropriate by the investigator based upon the results of participant's self-monitored blood glucose levels but not to exceed 6 mg/day."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "138"}, {"groupId": "OG001", "value": "137"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "81.2"}, {"groupId": "OG001", "value": "40.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "paramType": "Difference in percent", "paramValue": "41.01", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "30.0", "ciUpperLimit": "51.0"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to 32 weeks", "description": "The APaT Population includes all randomized participants who received at least 1 dose of study medication.", "eventGroups": [{"id": "EG000", "title": "Sitagliptin/Metformin", "description": "Participants in the Sitagliptin/Metformin Fixed- Dose Combination (Sita/Met FDC) group received tablets of Sita/Met FDC and placebo tablets matching glimepiride for 30 weeks. The dose for Sita/Met FDC was 50/500 mg twice daily (b.i.d.) starting Day 1 and increased to 50/1000 mg b.i.d. over a period of 4 weeks.", "seriousNumAffected": 8, "seriousNumAtRisk": 146, "otherNumAffected": 62, "otherNumAtRisk": 146}, {"id": "EG001", "title": "Glimepiride", "description": "Participants in the Glimepiride group received 2 placebo tablets matching Sita/Met FDC and glimepiride tablets (1 mg or 2 mg) for 30 weeks. The dose for glimepiride was 1 mg once daily (q.d.) starting Day 1 and up-titrated as considered appropriate by the investigator based upon the results of participant's self-monitored blood glucose levels but not to exceed 6 mg/day.", "seriousNumAffected": 9, "seriousNumAtRisk": 144, "otherNumAffected": 54, "otherNumAtRisk": 144}], "seriousEvents": [{"term": "DUODENAL ULCER HAEMORRHAGE", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 146}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 144}]}, {"term": "PANCREATITIS ACUTE", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 146}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 144}]}, {"term": "ENTEROCOLITIS INFECTIOUS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 146}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 144}]}, {"term": "HERPES ZOSTER", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 146}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 144}]}, {"term": "INFECTIVE SPONDYLITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 146}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 144}]}, {"term": "INFLUENZA", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 146}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 144}]}, {"term": "CARTILAGE INJURY", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 146}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 144}]}, {"term": "CONTUSION", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 146}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 144}]}, {"term": "OVERDOSE", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 146}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 144}]}, {"term": "HYPERGLYCAEMIA", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 146}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 144}]}, {"term": "GOUTY ARTHRITIS", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 146}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 144}]}, {"term": "SPONDYLOLISTHESIS", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 146}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 144}]}, {"term": "PAPILLARY THYROID CANCER", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 146}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 144}]}, {"term": "SQUAMOUS CELL CARCINOMA", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 146}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 144}]}, {"term": "THYROID CANCER", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 146}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 144}]}, {"term": "UTERINE LEIOMYOMA", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 146}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 144}]}, {"term": "INTRACRANIAL ANEURYSM", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 146}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 144}]}, {"term": "SYNCOPE", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 146}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 144}]}, {"term": "URINARY INCONTINENCE", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 146}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 144}]}, {"term": "URTICARIA", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 146}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 144}]}], "otherEvents": [{"term": "DIARRHOEA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 22, "numAffected": 15, "numAtRisk": 146}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 144}]}, {"term": "DYSPEPSIA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 20, "numAffected": 19, "numAtRisk": 146}, {"groupId": "EG001", "numEvents": 10, "numAffected": 9, "numAtRisk": 144}]}, {"term": "NAUSEA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 12, "numAffected": 10, "numAtRisk": 146}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 144}]}, {"term": "NASOPHARYNGITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 19, "numAffected": 13, "numAtRisk": 146}, {"groupId": "EG001", "numEvents": 22, "numAffected": 17, "numAtRisk": 144}]}, {"term": "UPPER RESPIRATORY TRACT INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 13, "numAffected": 12, "numAtRisk": 146}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 144}]}, {"term": "HYPOGLYCAEMIA", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 16.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 12, "numAffected": 8, "numAtRisk": 146}, {"groupId": "EG001", "numEvents": 53, "numAffected": 29, "numAtRisk": 144}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp.", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Korea, Republic of"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}, {"id": "C000057619", "term": "Glimepiride"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000007166", "term": "Immunosuppressive Agents"}, {"id": "D000007155", "term": "Immunologic Factors"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Percutaneous", "relevance": "HIGH"}, {"id": "M252104", "name": "Glimepiride", "asFound": "Bioequivalence", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}